For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Standard BioTools Inc (NASDAQ: LAB) closed at $1.87 down -6.97% from its previous closing price of $2.01. In other words, the price has decreased by -$6.97 from its previous closing price. On the day, 1.31 million shares were traded. LAB stock price reached its highest trading level at $2.0 during the session, while it also had its lowest trading level at $1.86.
Ratios:
For a deeper understanding of Standard BioTools Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.53 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 16, 2024, initiated with a Buy rating and assigned the stock a target price of $3.50.
On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.
On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.KeyBanc Capital Markets initiated its Overweight rating on July 12, 2023, with a $4 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 09 ’24 when Taich Adam bought 45,851 shares for $2.00 per share.
Casdin Partners Master Fund, L bought 250,000 shares of LAB for $546,750 on Aug 27 ’24. The Director now owns 54,025,821 shares after completing the transaction at $2.19 per share. On Aug 23 ’24, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 292,100 shares for $2.13 each. As a result, the insider paid 620,975 and bolstered with 53,625,821 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 694057920 and an Enterprise Value of 226536240. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.09 while its Price-to-Book (P/B) ratio in mrq is 1.36. Its current Enterprise Value per Revenue stands at 1.662 whereas that against EBITDA is -2.172.
Stock Price History:
Over the past 52 weeks, LAB has reached a high of $3.04, while it has fallen to a 52-week low of $1.21. The 50-Day Moving Average of the stock is -5.84%, while the 200-Day Moving Average is calculated to be -17.68%.
Shares Statistics:
For the past three months, LAB has traded an average of 3.25M shares per day and 1644800 over the past ten days. A total of 371.15M shares are outstanding, with a floating share count of 359.12M. Insiders hold about 3.24% of the company’s shares, while institutions hold 72.50% stake in the company. Shares short for LAB as of 1724976000 were 22232330 with a Short Ratio of 6.85, compared to 1722384000 on 19405603. Therefore, it implies a Short% of Shares Outstanding of 22232330 and a Short% of Float of 12.34.
